Inclusion Criteria:

- History of malignant glioma (WHO Grade III or IV) of the brain treated with some
combination of surgery, biochemotherapy and conventionally fractionated external beam
radiotherapy

- Radiotherapy completed at least 6 months prior to recurrence

- Age 18 years and older

- New or enlarging contrast-enhancing and/or 18FDG-avid nodule, at least 1 cm diameter

- Estimated life expectancy of 3 months or longer

Exclusion Criteria:

- Avastin therapy within 21 days of start of participation

- Contraindication to Avastin therapy or brain MRI

- Presence of bleeding diathesis or coagulopathy

- History of prior arterial thrombotic event, myocardial infarction, angina, CVA, TIA,
CABG angioplasty or stenting within 6 months.

- Inadequately controlled hypertension (defined as systolic blood pressure

- New York Heart Association (NYHA) Grade II or greater congestive heart failure

- Clinically significant vascular disease

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to onset of treatment

- Prior history of hypertensive crisis or hypertensive encephalopathy

- History of abdominal fistula or GI perforation within 6 months prior to onset of
treatment

- Serious non-healing wound, active ulcer or untreated bone fracture

- Proteinuria demonstrated by Urine Protein Creatinine ratio > 1.0

- Pregnancy